Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

zirconium Zr 89-DFO-fianlimab

A radioimmunoconjugate consisting of fianlimab, a human monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene-3 protein (LAG-3; LAG3; CD223), linked, via the chelator desferrioxamine (DFO), to the positron-emitting radionuclide zirconium Zr 89 (Zr89), with potential use as an imaging agent upon positron emission tomography (PET) imaging. Upon administration of zirconium Zr 89-DFO- fianlimab, the fianlimab moiety specifically targets and binds to LAG-3. Upon binding, the radioisotope moiety may be detected using PET, thereby allowing the imaging and quantification of LAG-3-expressing tumor infiltrating lymphocytes (TILs). LAG-3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells; its expression on TILs is associated with tumor-mediated immune suppression and the negative regulation of both cellular proliferation and T-cell activation.
Synonym:89Zr-DFO-fianlimab
89Zr-DFO-REGN3767
Search NCI's Drug Dictionary